Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
ERYTECH Pharma S.A is a biotechnology business based in the US. ERYTECH Pharma S-A shares (ERYP) are listed on the NASDAQ and all prices are listed in US Dollars. ERYTECH Pharma S-A employs 196 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.48|
|52-week range||$4.10 - $13.00|
|50-day moving average||$6.07|
|200-day moving average||$5.92|
|Wall St. target price||$17.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.69|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-9.57%|
|1 month (2021-09-23)||-9.42%|
|3 months (2021-07-23)||15.37%|
|6 months (2021-04-23)||-24.83%|
|1 year (2020-10-23)||-12.04%|
|2 years (2019-10-21)||27.74%|
|3 years (2018-10-23)||7.08|
|5 years (2016-10-19)||N/A|
|Revenue TTM||$4.1 million|
|Gross profit TTM||$3.7 million|
|Return on assets TTM||-45.13%|
|Return on equity TTM||-151.57%|
|Market capitalisation||$170.5 million|
TTM: trailing 12 months
There are currently 15,466 ERYTECH Pharma S-A shares held short by investors – that's known as ERYTECH Pharma S-A's "short interest". This figure is 30.6% down from 22,299 last month.
There are a few different ways that this level of interest in shorting ERYTECH Pharma S-A shares can be evaluated.
ERYTECH Pharma S-A's "short interest ratio" (SIR) is the quantity of ERYTECH Pharma S-A shares currently shorted divided by the average quantity of ERYTECH Pharma S-A shares traded daily (recently around 48331.25). ERYTECH Pharma S-A's SIR currently stands at 0.32. In other words for every 100,000 ERYTECH Pharma S-A shares traded daily on the market, roughly 320 shares are currently held short.
However ERYTECH Pharma S-A's short interest can also be evaluated against the total number of ERYTECH Pharma S-A shares, or, against the total number of tradable ERYTECH Pharma S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ERYTECH Pharma S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ERYTECH Pharma S-A shares in existence, roughly 0 shares are currently held short) or 0.0008% of the tradable shares (for every 100,000 tradable ERYTECH Pharma S-A shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ERYTECH Pharma S-A.
Find out more about how you can short ERYTECH Pharma S-A stock.
We're not expecting ERYTECH Pharma S-A to pay a dividend over the next 12 months.
Over the last 12 months, ERYTECH Pharma S-A's shares have ranged in value from as little as $4.1 up to $13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ERYTECH Pharma S-A's is 1.9201. This would suggest that ERYTECH Pharma S-A's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ERYTECH Pharma S. A. , a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.